Title: Endoscopic ultrasound-guided ethanol VS ethanol combined with paclitaxel for the
ablation of Pancreatic Cystic Lesions: A Systematic Review and Meta-Analysis
Version: 1 Date: 17 Jan 2025
Reviewer's report:
I read with great interest the meta-analysis on Endoscopic ultrasound-guided ethanol versus
ethanol combined with paclitaxel for the ablation of Pancreatic Cystic Lesions by Ding et al.  I
have few comments for the authors:
1. Abstract: change 11 to Eleven (line 23)
2. The title denotes this to be a comparison between 2 treatment modalities. Please mention
whether the primary outcome is the “overall” cyst resolution rate OR whether it’s a comparison
between 2 treatment modalities. Kindly rephrase the result section accordingly in the abstract
(line 24: mentioned as sub-group analysis).
3. PROSPERO registry: one cannot have same intervention and control arms. Please check
and rectify this. Moreover, analysis of sub-group mentions “NO” in the protocol, which is
contradictory.
4. Which quality assessment was used for RCTs ? NOS is usually used for non-randomized
studies (line 104)
5. Line 117: Spelling of pancreatitis
6. Please calculate the mean follow up duration for both treatment arms and mention in the
results.
7. If possible and data is available, please report sub-group analysis of IPMN cysts comparing
ethanol vs ethanol and paclitaxel as well as overall results of EUS-ablation
Title: Endoscopic ultrasound-guided ethanol VS ethanol combined with paclitaxel for the
ablation of Pancreatic Cystic Lesions: A Systematic Review and Meta-Analysis
Version: 1 Date: 17 Jan 2025
Reviewer's report:
I read with great interest the meta-analysis on Endoscopic ultrasound-guided ethanol versus
ethanol combined with paclitaxel for the ablation of Pancreatic Cystic Lesions by Ding et al.  I
have few comments for the authors:
1. Abstract: change 11 to Eleven (line 23)
2. The title denotes this to be a comparison between 2 treatment modalities. Please mention
whether the primary outcome is the “overall” cyst resolution rate OR whether it’s a comparison
between 2 treatment modalities. Kindly rephrase the result section accordingly in the abstract
(line 24: mentioned as sub-group analysis).
3. PROSPERO registry: one cannot have same intervention and control arms. Please check
and rectify this. Moreover, analysis of sub-group mentions “NO” in the protocol, which is
contradictory.
4. Which quality assessment was used for RCTs ? NOS is usually used for non-randomized
studies (line 104)
5. Line 117: Spelling of pancreatitis
6. Please calculate the mean follow up duration for both treatment arms and mention in the
results.
7. If possible and data is available, please report sub-group analysis of IPMN cysts comparing
ethanol vs ethanol and paclitaxel as well as overall results of EUS-ablation
Please review this paper.
user
Title: Endoscopic ultrasound-guided ethanol VS ethanol combined with paclitaxel for the
ablation of Pancreatic Cystic Lesions: A Systematic Review and Meta-Analysis
Version: 1 Date: 17 Jan 2025
Reviewer's report:
I read with great interest the meta-analysis on Endoscopic ultrasound-guided ethanol versus
ethanol combined with paclitaxel for the ablation of Pancreatic Cystic Lesions by Ding et al.  I
have few comments for the authors:
1. Abstract: change 11 to Eleven (line 23)
2. The title denotes this to be a comparison between 2 treatment modalities. Please mention
whether the primary outcome is the “overall” cyst resolution rate OR whether it’s a comparison
between 2 treatment modalities. Kindly rephrase the result section accordingly in the abstract
(line 24: mentioned as sub-group analysis).
3. PROSPERO registry: one cannot have same intervention and control arms. Please check
and rectify this. Moreover, analysis of sub-group mentions “NO” in the protocol, which is
contradictory.
4. Which quality assessment was used for RCTs ? NOS is usually used for non-randomized
studies (line 104)
5. Line 117: Spelling of pancreatitis
6. Please calculate the mean follow up duration for both treatment arms and mention in the
results.
7. If possible and data is available, please report sub-group analysis of IPMN cysts comparing
ethanol vs ethanol and paclitaxel as well as overall results of EUS-ablation
assistant